Which drug better protects GCA Patients' hearts? large study investigates
NCT ID NCT07459335
First seen Mar 12, 2026 · Last updated Jun 08, 2026 · Updated 17 times
Summary
This study looked at over 1,600 people with giant cell arteritis (GCA), a condition that causes blood vessel inflammation and raises heart risks. Researchers compared two treatments—tocilizumab and methotrexate—to see which one better prevented heart attacks, strokes, or death. Using French national health data, they found no major difference between the two drugs for these outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP_ Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
APHP_ Hôpital Saint-Antoine
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.